Europe-Africa Research Network for Evaluation of Second-line Therapy
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The trial aim is to ascertain what, if anything, needs to be combined with a boosted protease
inhibitor (bPI) backbone in second-line therapy in order to maximize the chance of a good
clinical outcome following WHO-defined failure on a first-line nucleoside reverse
transcriptase inhibitor (NRTI) and NNRTI-containing regimen with probable extensive NRTI and
NNRTI resistance mutations.
Phase:
Phase 3
Details
Lead Sponsor:
Justine Boles
Collaborator:
European and Developing Countries Clinical Trials Partnership (EDCTP)